Komodo-Powered Research at ISPOR: The Future of Real-World Evidence
Real-world evidence is making good on its promise to transform healthcare. Whether that’s to identify historically underrepresented patient populations, optimize clinical trials to improve outcomes, or deploy informed commercial strategies to ensure patients have access to the therapies and treatments they need, RWE is a cornerstone for Life Sciences organizations. Yet the insights unlocked are only as good as the foundation upon which they are built.
Nowhere is this more evident than in Health Economics Outcomes Research (HEOR). Access to near real-time evidence from patient journeys can circumvent the data lag seen in traditional sources, giving researchers the capacity to answer in-depth questions about what’s happening for patients now. Highly connected, comprehensive data from diverse sources can offer longitudinal views with more breadth, and the ability to link together disparate data sources makes insights not only deeper and more reliable, but more nuanced. Couple these with advances in analytics, software, and technology, and insights are more robust than ever before.
Komodo Health has partnered with RWE and HEOR teams, both in the U.S. and globally, to power peer-reviewed research, and to help answer some of medicine’s most pressing questions. Insights from Komodo's Healthcare Map uncovered crucial findings for a number of studies being presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022 conference. Our technology helped answer questions like, “Do certain drugs to prevent bone loss affect the impact of COVID?” “How has the pandemic impacted telehealth utilization?” “How has the utilization of cell and gene therapy changed over the last five years?” and “How do different treatment approaches affect outcomes for patients with Non-Alcoholic Steatohepatitis (NASH)?”
Here’s a look at some of the Komodo-powered research being presented at ISPOR this year:
- Veradigm Life Sciences and Madrigal Pharma conducted a study, “Assessing Cardiovascular Disease (CVD) Risk By Fibrosis Stage Defined By Fibrosis-4 (FIB-4) Among Patients with Non-Alcoholic Steatohepatitis (NASH),” using a new epidemiology research approach to assess the association between CVD risk and fibrosis stage in patients with varying stages of NASH. Komodo’s real-world patient journey data was linked to electronic health records from Veradigm to identify NASH patients with a minimum of six months of database activity and continuous enrollment pre- and post-diagnosis. They found that NASH patients with a more advanced fibrosis stage had a substantially higher risk of CVD, leading the way for clinical validation that may impact the risk and burden of CVD.
- Cerner Enviza (formerly Kantar Health) and Harvard Medical School published a poster, “Association Between Prior Bisphosphonate Use and COVID-19-Related Outcomes,” which used Komodo’s Healthcare Map to study the association between the use of Bisphosphonates (BP), a common class of osteoporosis drugs that prevents bone density loss, and COVID-19-related outcomes. Analyses of the treatment group and control group, each with over 450k patients, found that prior BP use was associated with a reduced odds of COVID-19-related outcomes.
- Trinity Life Sciences’ poster titled, “Trends in Cell and Gene Therapy Uptake and Utilization in the United States: A Real-World Analysis of the Komodo Healthcare MapTM claims Data from 2015-2021,” describes their study to track the real-world use of cell and gene therapies. Using Komodo’s Healthcare Map, this study sought to understand the uptake of cell and gene therapy (CGT), which had not been well quantified in a real-world setting. Over 20k patients were identified from more than 150 million unique patient journeys to analyze their utilization of seven CGTs. A steady year-over-year increase in CGTs was identified, along with the primary physician specialties prescribing them: urology, orthopedics, and hematology/oncology.
- Pfizer, Statistical Research and Data Science Center’s study “Real-World Utilization Patterns of Oncology Biosimilar Monoclonal Antibodies and Their Corresponding Reference Products,” used closed claims data from Komodo’s Healthcare Map between 2018 and 2021 to elucidate the real-world treatment patterns of monoclonal antibodies (mAbs) in cancer patients. This included describing the time-to-therapy initiation after diagnosis, concomitant medication use, and switching patterns. The findings indicated that the utilization of biosimilar-mAb products is being done in a similar way to reference biologic-mAbs in real-world clinical settings.
At Komodo, we’re paving the way for a new frontier of health research, strengthening our collective understanding of the clinical and economic impacts of various therapies across multiple subsets of the population. Ultimately, these are essential insights in an industry that is working to reduce the global burden of disease.